Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

BACKGROUND: As the first non‐factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. OBJECTIVES: We applied an algorithm for categorization of fatal events contemporaneous to emicizumab using reporter‐a...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyvandi, Flora, Mahlangu, Johnny N., Pipe, Steven W., Hay, Charles R. M., Pierce, Glenn F., Kuebler, Peter, Kruse‐Jarres, Rebecca, Shima, Midori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756327/
https://www.ncbi.nlm.nih.gov/pubmed/33331041
http://dx.doi.org/10.1111/jth.15187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756327/
https://www.ncbi.nlm.nih.gov/pubmed/33331041
http://dx.doi.org/10.1111/jth.15187

Ejemplares similares